445 related articles for article (PubMed ID: 11723140)
1. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
Zhong D; Bajaj MS; Schmidt AE; Bajaj SP
J Biol Chem; 2002 Feb; 277(5):3622-31. PubMed ID: 11723140
[TBL] [Abstract][Full Text] [Related]
2. Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.
Ndonwi M; Broze GJ; Agah S; Schmidt AE; Bajaj SP
J Biol Chem; 2007 May; 282(21):15632-44. PubMed ID: 17387172
[TBL] [Abstract][Full Text] [Related]
3. Role of the Gla and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes.
Thiec F; Cherel G; Christophe OD
J Biol Chem; 2003 Mar; 278(12):10393-9. PubMed ID: 12529356
[TBL] [Abstract][Full Text] [Related]
4. The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII--tissue factor complex.
Ndonwi M; Broze G; Bajaj SP
J Thromb Haemost; 2005 Jan; 3(1):112-8. PubMed ID: 15634274
[TBL] [Abstract][Full Text] [Related]
5. Structural biology of factor VIIa/tissue factor initiated coagulation.
Vadivel K; Bajaj SP
Front Biosci (Landmark Ed); 2012 Jun; 17(7):2476-94. PubMed ID: 22652793
[TBL] [Abstract][Full Text] [Related]
6. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X.
Huang Q; Neuenschwander PF; Rezaie AR; Morrissey JH
J Biol Chem; 1996 Sep; 271(36):21752-7. PubMed ID: 8702971
[TBL] [Abstract][Full Text] [Related]
7. Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X.
Persson KE
Scand J Clin Lab Invest Suppl; 2002; 237():13-8. PubMed ID: 12570162
[TBL] [Abstract][Full Text] [Related]
8. Model of a ternary complex between activated factor VII, tissue factor and factor IX.
Chen SW; Pellequer JL; Schved JF; Giansily-Blaizot M
Thromb Haemost; 2002 Jul; 88(1):74-82. PubMed ID: 12152682
[TBL] [Abstract][Full Text] [Related]
9. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
Norledge BV; Petrovan RJ; Ruf W; Olson AJ
Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
Prasad R; Sen P
Phys Chem Chem Phys; 2017 Aug; 19(33):22230-22242. PubMed ID: 28799584
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
12. Solution structure of the N-terminal EGF-like domain from human factor VII.
Muranyi A; Finn BE; Gippert GP; Forsén S; Stenflo J; Drakenberg T
Biochemistry; 1998 Jul; 37(30):10605-15. PubMed ID: 9692950
[TBL] [Abstract][Full Text] [Related]
13. Structure-function relationships in factor IX and factor IXa.
Schmidt AE; Bajaj SP
Trends Cardiovasc Med; 2003 Jan; 13(1):39-45. PubMed ID: 12554099
[TBL] [Abstract][Full Text] [Related]
14. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.
Zhong D; Smith KJ; Birktoft JJ; Bajaj SP
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3574-8. PubMed ID: 8170949
[TBL] [Abstract][Full Text] [Related]
15. The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.
Fribourg C; Meijer AB; Mertens K
Biochemistry; 2006 Sep; 45(35):10777-85. PubMed ID: 16939230
[TBL] [Abstract][Full Text] [Related]
16. Identification of a basic region on tissue factor that interacts with the first epidermal growth factor-like domain of factor X.
Manithody C; Yang L; Rezaie AR
Biochemistry; 2007 Mar; 46(11):3193-9. PubMed ID: 17323935
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the EGF-like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B.
Knobe KE; Persson KE; Sjörin E; Villoutreix BO; Stenflo J; Ljung RC
J Thromb Haemost; 2003 Apr; 1(4):782-90. PubMed ID: 12871416
[TBL] [Abstract][Full Text] [Related]
18. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.
Toso R; Pinotti M; High KA; Pollak ES; Bernardi F
Biochem J; 2002 Apr; 363(Pt 2):411-6. PubMed ID: 11931672
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy.
Lazarus RA; Olivero AG; Eigenbrot C; Kirchhofer D
Curr Med Chem; 2004 Sep; 11(17):2275-90. PubMed ID: 15379712
[TBL] [Abstract][Full Text] [Related]
20. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
Jin J; Perera L; Stafford D; Pedersen L
J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
